Latest Financials News

ParagonCare has released its audited FY25 financial results, confirming steady profit while revealing a significant reclassification of debt and ongoing challenges with a major retail pharmacy receivable.

Myer Holdings has clarified that its FY2025 earnings aligned with market forecasts, addressing concerns following a sharp share price drop after its results announcement.

Linius Technologies has released its audited FY2025 financial statements, revealing non-cash accounting adjustments related to Convertible Notes that increased reported losses and liabilities compared to prior unaudited figures.

Ryzon Materials has expanded its engineering contract with Xinhai to fast track production at its Nachu Graphite Project, alongside a $500,000 capital raising from Xinhai. The deal involves a $3.5 million contract largely settled through shares and options, pending shareholder approval.

Dalrymple Bay Infrastructure has appointed CEO Michael Riches as Managing Director, coinciding with the resignation of two non-executive directors following a significant shareholder sell-down.

Peak Rare Earths has officially been acquired by Shenghe Resources, with shareholders paid $0.443 per share and delisting from the ASX imminent. This marks a significant consolidation in the rare earths sector.

The Star Entertainment Group has finalized a crucial covenant waiver with its syndicated lenders, easing financial pressures ahead of its FY2025 audited report. This development clarifies ongoing negotiations and sets the stage for the company’s next financial chapter.

Uscom Limited has struck a deal to sell its entire business to Singapore-based AXO Medtech VCC for $2.59 million, aiming to unlock capital for growth under new ownership. Shareholder approval is the next critical step before the transaction can proceed.

Invex Therapeutics Ltd has had its trading suspension lifted following the announcement of a material acquisition, signaling a pivotal moment for the biotech company.

Hydrix Limited delays its FY25 financial statements due to a pending independent valuation of its Wavewise Analytics shareholding, triggering an automatic trading suspension from 1 October 2025.

Starpharma has entered a strategic research and option agreement with Radiopharm Theranostics to develop a novel radiotherapy asset using its proprietary dendrimer technology, unlocking potential milestone payments of up to AUD $89 million.

Spirit Technology Solutions forecasts strong FY26 growth with revenue surpassing $114 million and underlying EBITDA rising between 14% and 23%. The company signals ongoing expansion through organic and potential inorganic avenues.